𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levetiracetam in tardive dyskinesia: An open label study

✍ Scribed by Spiros Konitsiotis; Sofia Pappa; Christos Mantas; Venos Mavreas

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
53 KB
Volume
21
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia were evaluated in an open label study. Eight patients received oral LEV (1,000 mg/day) for 1 month and blinded evaluations were performed at baseline and at the end of the treatment period. A significant reduction of the abnormal movements was recorded while psychiatric symptoms did not worsen and the adverse event profile was benign. LEV may be efficacious for the treatment of tardive dyskinesia and deserves further clinical testing.

πŸ“œ SIMILAR VOLUMES

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; John L. Maldonado; William O. Tatum; Ro πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

## Abstract We evaluated the tolerability and preliminary efficacy of levetiracetam (LEV; Keppra) in reducing levodopa‐induced dyskinesias in Parkinson's disease (PD) in an open‐label pilot study. Nine PD patients who were experiencing peak‐dose dyskinesias for at least 25% of the awake day and wer

Metoclopramide-induced tardive dyskinesi
Metoclopramide-induced tardive dyskinesia in an infant
✍ Nicte I. Mejia; Joseph Jankovic πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 63 KB πŸ‘ 1 views

## Abstract We describe a 1‐year‐old girl who developed orofaciolingual stereotypy at age 2 months after a 17‐day treatment with metoclopramide for gastroesophageal reflux. The stereotypy, documented by sequential videos, persisted for at least 9 months after the drug was discontinued. This patient

An open-label study of quetiapine in ano
An open-label study of quetiapine in anorexia nervosa
✍ P. Bosanac; S. Kurlender; T. Norman; K. Hallam; K. Wesnes; T. Manktelow; G. Burr πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

## Abstract ## Background Atypical antipsychotics may be beneficial in treating the core psychopathology of anorexia nervosa (AN). ## Methods An 8 week open‐label study of quetiapine was conducted in eight severely ill DSM‐IV AN patients consecutively admitted to a specialist eating disorders un

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 65 KB πŸ‘ 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

A pilot study of verapamil in the treatm
A pilot study of verapamil in the treatment of tardive dyskinesia
✍ Timothy G. Dinan; Claire Capstick πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 237 KB πŸ‘ 1 views

Six patients with severe and stable tardive dyskinesia were treated with verapamil, a calcium channel blocker, in doses ranging from 240 to 400 mg/day. Weekly assessments were made using the Simpson tardive dyskinesia rating scale. Neuroleptic medication was held constant during the 3-month baseline